Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

The tumor suppressor RhoBTB1 controls Golgi integrity and breast cancer cell invasion through METTL7B

Authors: Caroline M. McKinnon, Harry Mellor

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

RhoBTB1 and 2 are atypical members of the Rho GTPase family of signaling proteins. Unlike other Rho GTPases, RhoBTB1 and 2 undergo silencing or mutation in a wide range of epithelial cancers; however, little is known about the consequences of this loss of function.

Methods

We analyzed transcriptome data to identify transcriptional targets of RhoBTB2. We verified these using Q-PCR and then used gene silencing and cell imaging to determine the cellular function of these targets downstream of RhoBTB signaling.

Results

RhoBTB1 and 2 regulate the expression of the methyltransferases METTL7B and METTL7A, respectively. RhoBTB1 regulates the integrity of the Golgi complex through METTL7B. RhoBTB1 is required for expression of METTL7B and silencing of either protein leads to fragmentation of the Golgi. Loss of RhoBTB1 expression is linked to Golgi fragmentation in breast cancer cells. Restoration of normal RhoBTB1 expression rescues Golgi morphology and dramatically inhibits breast cancer cell invasion.

Conclusion

Loss of RhoBTB1 expression in breast cancer cells leads to Golgi fragmentation and hence loss of normal polarity.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
Wherlock M, Mellor H. The Rho GTPase family: a racs to wrchs story. J Cell Sci. 2002;115(Pt 2):239–40.PubMed
5.
Ramos S, Khademi F, Somesh BP, Rivero F. Genomic organization and expression profile of the small GTPases of the RhoBTB family in human and mouse. Gene. 2002;298(2):147–57.CrossRefPubMed
6.
Ji W, Rivero F. Atypical Rho GTPases of the RhoBTB Subfamily: Roles in Vesicle Trafficking and Tumorigenesis. Cells. 2016;5(2).
7.
Hamaguchi M, Meth JL, von Klitzing C, Wei W, Esposito D, Rodgers L, et al. DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci U S A. 2002;99(21):13647–52.CrossRefPubMedPubMedCentral
8.
Freeman SN, Cress WD. RhoBTB2 (DBC2) comes of age as a multifunctional tumor suppressor. Cancer Biol Ther. 2010;10(11):1123–5.CrossRefPubMed
9.
Knowles MA, Aveyard JS, Taylor CF, Harnden P, Bass S. Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. Cancer Lett. 2005;225(1):121–30.CrossRefPubMed
10.
Mao H, Qu X, Yang Y, Zuo W, Bi Y, Zhou C, et al. A novel tumor suppressor gene RhoBTB2 (DBC2): frequent loss of expression in sporadic breast cancer. Mol Carcinog. 2010;49(3):283–9.PubMed
11.
Tang W, Wang C, Fu F, Chen Q. RhoBTB2 gene in breast cancer is silenced by promoter methylation. Int J Mol Med. 2014;33(3):722–8.PubMed
12.
Beder LB, Gunduz M, Ouchida M, Gunduz E, Sakai A, Fukushima K, et al. Identification of a candidate tumor suppressor gene RHOBTB1 located at a novel allelic loss region 10q21 in head and neck cancer. J Cancer Res Clin Oncol. 2006;132(1):19–27.CrossRefPubMed
13.
Xu RS, Wu XD, Zhang SQ, Li CF, Yang L, Li DD, et al. The tumor suppressor gene RhoBTB1 is a novel target of miR-31 in human colon cancer. Int J Oncol. 2013;42(2):676–82.PubMed
14.
Aspenstrom P, Fransson A, Saras J. Rho GTPases have diverse effects on the organization of the actin filament system. Biochem J. 2004;377(Pt 2):327–37.CrossRefPubMedPubMedCentral
15.
Perez-Torrado R, Yamada D, Defossez PA. Born to bind: the BTB protein-protein interaction domain. Bioessays. 2006;28(12):1194–202.CrossRefPubMed
16.
McKinnon CM, Lygoe KA, Skelton L, Mitter R, Mellor H. The atypical Rho GTPase RhoBTB2 is required for expression of the chemokine CXCL14 in normal and cancerous epithelial cells. Oncogene. 2008;27(54):6856–65.CrossRefPubMed
17.
Blaschke RJ, Howlett AR, Desprez PY, Petersen OW, Bissell MJ. Cell differentiation by extracellular matrix components. Methods Enzymol. 1994;245:535–56.CrossRefPubMed
18.
Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods. 2003;30(3):256–68.CrossRefPubMed
19.
Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C, et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther. 2002;13(7):803–13.CrossRefPubMed
20.
Wu CC, MacCoss MJ, Mardones G, Finnigan C, Mogelsvang S, Yates 3rd JR, et al. Organellar proteomics reveals Golgi arginine dimethylation. Mol Biol Cell. 2004;15(6):2907–19.CrossRefPubMedPubMedCentral
21.
Radeke HS, Digits CA, Casaubon RL, Snapper ML. Interactions of (−)-ilimaquinone with methylation enzymes: implications for vesicular-mediated secretion. Chem Biol. 1999;6(9):639–47.CrossRefPubMed
22.
Zehmer JK, Bartz R, Liu P, Anderson RG. Identification of a novel N-terminal hydrophobic sequence that targets proteins to lipid droplets. J Cell Sci. 2008;121(Pt 11):1852–60.CrossRefPubMedPubMedCentral
23.
Han L, Hou L, Song J, Lin D, Wu L, Ge Y, et al. Decreased expression of the DBC2 gene and its clinicopathological significance in breast cancer: correlation with aberrant DNA methylation. Biotechnol Lett. 2013;35(8):1175–81.CrossRefPubMed
24.
Ohadi M, Totonchi M, Maguire P, Lindblom A, Habibi R, Alavi BA, et al. Mutation analysis of the DBC2 gene in sporadic and familial breast cancer. Acta Oncol. 2007;46(6):770–2.CrossRefPubMed
25.
Soule HD, Maloney TM, Wolman SR, Peterson Jr WD, Brenz R, McGrath CM, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990;50(18):6075–86.PubMed
26.
Briand P, Petersen OW, Van Deurs B. A new diploid nontumorigenic human breast epithelial cell line isolated and propagated in chemically defined medium. In Vitro Cell Dev Biol. 1987;23(3):181–8.CrossRefPubMed
27.
Yadav S, Puri S, Linstedt AD. A primary role for Golgi positioning in directed secretion, cell polarity, and wound healing. Mol Biol Cell. 2009;20(6):1728–36.CrossRefPubMedPubMedCentral
28.
29.
Yadav S, Linstedt AD. Golgi positioning. Cold Spring Harb Perspect Biol. 2011;3(5).
30.
Kleinman HK, Martin GR. Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol. 2005;15(5):378–86.CrossRefPubMed
31.
32.
Genschik P, Sumara I, Lechner E. The emerging family of CULLIN3-RING ubiquitin ligases (CRL3s): cellular functions and disease implications. EMBO J. 2013;32(17):2307–20.CrossRefPubMedPubMedCentral
33.
Berthold J, Schenkova K, Ramos S, Miura Y, Furukawa M, Aspenstrom P, et al. Characterization of RhoBTB-dependent Cul3 ubiquitin ligase complexes--evidence for an autoregulatory mechanism. Exp Cell Res. 2008;314(19):3453–65.CrossRefPubMedPubMedCentral
34.
35.
Kelly KF, Daniel JM. POZ for effect--POZ-ZF transcription factors in cancer and development. Trends Cell Biol. 2006;16(11):578–87.CrossRefPubMed
36.
Espinosa EJ, Calero M, Sridevi K, Pfeffer SR. RhoBTB3: a Rho GTPase-family ATPase required for endosome to Golgi transport. Cell. 2009;137(5):938–48.CrossRefPubMedPubMedCentral
37.
38.
39.
40.
Puthenveedu MA, Bachert C, Puri S, Lanni F, Linstedt AD. GM130 and GRASP65-dependent lateral cisternal fusion allows uniform Golgi-enzyme distribution. Nat Cell Biol. 2006;8(3):238–48.CrossRefPubMed
41.
Diao A, Rahman D, Pappin DJ, Lucocq J, Lowe M. The coiled-coil membrane protein golgin-84 is a novel rab effector required for Golgi ribbon formation. J Cell Biol. 2003;160(2):201–12.CrossRefPubMedPubMedCentral
42.
Kupfer A, Louvard D, Singer SJ. Polarization of the Golgi apparatus and the microtubule-organizing center in cultured fibroblasts at the edge of an experimental wound. Proc Natl Acad Sci U S A. 1982;79:2603–07.
43.
Baschieri F, Confalonieri S, Bertalot G, Di Fiore PP, Dietmaier W, Leist M, et al. Spatial control of Cdc42 signalling by a GM130-RasGRF complex regulates polarity and tumorigenesis. Nat Commun. 2014;5:4839.CrossRefPubMedPubMedCentral
Metadata
Title
The tumor suppressor RhoBTB1 controls Golgi integrity and breast cancer cell invasion through METTL7B
Authors
Caroline M. McKinnon
Harry Mellor
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3138-3

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Review

Molecular chess? Hallmarks of anti-cancer drug resistance

Research article

Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study

Study protocol

Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08)

Research article

Evaluation of epidermal growth factor receptor signaling effects in gastric cancer cell lines by detailed motility-focused phenotypic characterization linked with molecular analysis

Research article

Genomic determinants of long-term cardiometabolic complications in childhood acute lymphoblastic leukemia survivors

Research article

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits